Letter to the EditorCombination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy
References (8)
Clin Gastroenterol Hepatol
(2018)Ann Intern Med
(2014)Inflamm Bowel Dis
(2007)Am J Gastroenterol
(2015)
Cited by (30)
Selective JAK1 inhibitors for the treatment of inflammatory bowel disease
2023, Pharmacology and TherapeuticsBreaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies
2023, Biomedicine and PharmacotherapyCitation Excerpt :At week 14, all patients showed improvement in IBD symptoms without signs of arthritis, pain, or joint swelling, and no adverse events during treatment. Two case reports in 2019 [106,107] published 2 successful cases of UC being treated with VDZ plus TOFA. Both patients presented with UC with seronegative HLA B27 inflammatory spondyloarthritis; no adverse events were reported.
What place for targeted treatment associations?
2022, Revue du Rhumatisme (Edition Francaise)Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review
2022, International ImmunopharmacologyCitation Excerpt :After primary screening, 226 studies were included for full-text analysis; 3 additional studies were identified from the reference lists of these studies. Eventually, 23 studies fulfilled the inclusion criteria [8–30]. A flow diagram reporting the literature search process is provided in Fig. 1.
Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
2022, Clinical Gastroenterology and HepatologyCitation Excerpt :A total of 39 reports of 30 studies met inclusion criteria (Figure 1) and were included for extraction and analysis. Of these, 14 case reports, 6 case series, 9 observational cohort studies, and 1 randomized controlled trial were identified.8,9,12–53 All 30 studies were included for qualitative analysis; 10 studies with 10 or more patients were identified and included for quantitative analysis.
Tofacitinib Is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis
2021, Clinical Gastroenterology and Hepatology
Conflicts of interest This author discloses the following: Laurent Peyrin-Biroulet has received honoraria from Pfizer and Takeda. The remaining authors disclose no conflicts.